Genotype and subependymal lesion burden influence volumetric response to everolimus in tuberous sclerosis complex-associated subependymal giant cell astrocytoma: A 10-year real-world study

Everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, effectively reduces subependymal giant cell astrocytoma (SEGA) volume in patients with tuberous sclerosis complex (TSC); however, biological determinants of therapeutic sensitivity remain poorly defined. In this 10-year real-world cohor...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Tzu-Hsuan Su, Steven Shinn-Forng Peng, Pei-Lung Chen, Shih-Hung Yang, Meng-Fai Kuo, Pi-Chuan Fan
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2026-04-01
Sarja:	Neurotherapeutics
Aiheet:	Tuberous sclerosis complex Subependymal giant cell astrocytoma Mechanistic target of rapamycin Everolimus mTOR inhibitor
Linkit:	http://www.sciencedirect.com/science/article/pii/S1878747926000966
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!